Infinity Pharmaceuticals to Participate in B. Riley Securities Virtual Oncology Investor Conference

Rhea-AI Summary

Infinity Pharmaceuticals (NASDAQ: INFI) will participate in a Fireside Chat with Andrew D’Silva from B. Riley Securities on January 20, 2021, at 10:30 am ET. The event is exclusively for institutional investors, investor relations, and company employees. A replay will be available on the Events and Presentations page post-conference. Infinity is focused on developing eganelisib, a first-in-class oral immuno-oncology treatment for cancer, currently in multiple clinical studies.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will participate in a Fireside Chat with Andrew D’Silva of B. Riley Securities on Wednesday, January 20, 2021 at 10:30 am ET.

B. Riley is limiting the live audience to institutional investors, investor relations, and employees of each presenting company. Private investors will not be given access to the live conference, but a replay will be available on the Events and Presentations page of the Infinity Pharmaceuticals website following the conference.

About Infinity and Eganelisib

Infinity is an innovative biopharmaceutical company dedicated to developing novel medicines for people with cancer. Infinity is advancing eganelisib, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-275 is a global, randomized, placebo-controlled study of eganelisib combined with Opdivo^® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq^® and Abraxane^® in front-line TNBC and in combination with Tecentriq and Avastin^® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (dual adenosine receptor antagonist) plus Doxil^® in advanced TNBC patients. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line and second line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo^® is a registered trademark of Bristol Myers Squibb.
Tecentriq^® is a registered trademark of Genentech, Inc.
Abraxane^® is a registered trademark of Abraxis BioScience, LLC.
Avastin^® is a registered trademark of Genentech, Inc.
Doxil^® is a registered trademark of Baxter Healthcare Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210115005108/en/

FAQ

What is the date of the upcoming Fireside Chat for Infinity Pharmaceuticals?

The Fireside Chat for Infinity Pharmaceuticals is scheduled for January 20, 2021.

Who will represent Infinity Pharmaceuticals in the Fireside Chat?

Andrew D’Silva from B. Riley Securities will represent Infinity Pharmaceuticals.

Will the Fireside Chat be accessible to private investors?

No, the Fireside Chat is limited to institutional investors, investor relations, and employees.

What is eganelisib and its significance for Infinity Pharmaceuticals?

Eganelisib is a first-in-class oral immuno-oncology candidate being developed for cancer treatment.

Where can I find the replay of the Fireside Chat?

The replay will be available on the Events and Presentations page of Infinity Pharmaceuticals' website.